Roles of the gut in the metabolic syndrome: an overview

Journal of Internal Medicine

Volumn 281, Issue 4, 2017, Pages 319-336

  Fandriks L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

body weight; chylomicrons; energy expenditure; food intake; glycaemia; metabolism

Indexed keywords

BILE ACID;

BARIATRIC SURGERY; CLINICAL FEATURE; DYSLIPIDEMIA; ENERGY EXPENDITURE; ENTERITIS; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HOST RESISTANCE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTESTINE FUNCTION; INTESTINE INNERVATION; LIPID METABOLISM; LIPID TRANSPORT; METABOLIC REGULATION; METABOLIC SYNDROME X; NON COMMUNICABLE DISEASE; OBESITY; PRIORITY JOURNAL; REVIEW; SYMBIOSIS; WEIGHT LOSS PROGRAM; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; COMORBIDITY; COMPLICATION; DIABETES MELLITUS; GASTROINTESTINAL TRACT; INFLAMMATION; METABOLISM; MICROBIOLOGY; MICROFLORA; RISK FACTOR;

ANIMALS; BARIATRIC SURGERY; BODY WEIGHT; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; GASTROINTESTINAL TRACT; HUMANS; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; MICROBIOTA; OBESITY; RISK FACTORS;

EID: 85015421425     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12584     Document Type: Review

References (142)

1. Rubino F, Nathan DM, Eckel RH et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016; 39: 861–77.
2. Hughes V. Weight-loss surgery: a gut-wrenching question. Nature 2014; 511: 282–4.
3. Puzziferri N, Roshek TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312: 934–42.
4. Henrikson V. Can small bowel resection be defended as therapy for obesity. Obes Surg 1994; 4: 54–5.
5. Longitudinal Assessment of Bariatric Surgery Consortium, Flum DR, Belle SH et al. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361(5): 445–54.
6. Olbers T, Bjorkman S, Lindroos A et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 2006; 244: 715–22.
7. Werling M, Fandriks L, Bjorklund P et al. Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty. Br J Surg 2013; 100: 222–30.
8. Miras AD, le Roux CW. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol 2013; 10: 575–84.
9. Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med 2013; 273: 219–34.
10. Lutz TA, Bueter M. The physiology underlying Roux-en-Y gastric bypass: a status report. Am J Physiol Regul Integr Comp Physiol 2014; 307: R1275–91.
11. Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 2016; 39: 893–901.
12. Cavin JB, Couvelard A, Lebtahi R et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose after Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology 2016; 150: 454–64 e9.
13. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–93.
14. Rubino F. Medical research: time to think differently about diabetes. Nature 2016; 533: 459–61.
15. WHO. Noncommunicable diseases. 2015. Available at http://www.who.int/mediacentre/factsheets/fs355/en/ (accessed June 12 2016).
16. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–5.
17. Kahn R. Metabolic syndrome–what is the clinical usefulness? Lancet 2008; 371: 1892–3.
18. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010; 375: 181–3.
19. Tenenbaum A, Fisman EZ. “The metabolic syndrome. is dead”: these reports are an exaggeration. Cardiovasc Diabetol 2011; 10: 11.
20. Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med 2016; 26: 364–73.
21. Sellayah D, Cagampang FR, Cox RD. On the evolutionary origins of obesity: a new hypothesis. Endocrinology 2014; 155: 1573–88.
22. Speakman JR. Evolutionary perspectives on the obesity epidemic: adaptive, maladaptive, and neutral viewpoints. Annu Rev Nutr 2013; 33: 289–317.
23. Lee IM, Shiroma EJ, Lobelo F et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380: 219–29.
24. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860–7.
25. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11: 738–49.
26. Castoldi A, Naffah de Souza C, Camara NO, Moraes-Vieira PM. The macrophage switch in obesity development. Front Immunol 2015; 6: 637.
27. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185–92.
28. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–72.
29. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link? Obes Rev 2011; 12: 449–58.
30. Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 2015; 48: 923–30.
31. Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: is it real and is it relevant? Biochimie 2016; 124: 11–20.
32. Luck H, Tsai S, Chung J et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab 2015; 21: 527–42.
33. Winer DA, Luck H, Tsai S, Winer S. The intestinal immune system in obesity and insulin resistance. Cell Metab 2016; 23: 413–26.
34. Lundberg JO, Weitzberg E. Biology of nitrogen oxides in the gastrointestinal tract. Gut 2013; 62: 616–29.
35. Nardone G, Compare D. The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases? United European Gastroenterol J 2015; 3: 255–60.
36. Mowat AM, Agace WW. Regional specialization within the intestinal immune system. Nat Rev Immunol 2014; 14: 667–85.
37. Woting A, Blaut M. The intestinal microbiota in metabolic disease. Nutrients 2016; 8: 202.
38. Camilleri M. Peripheral mechanisms in appetite regulation. Gastroenterology 2015; 148: 1219–33.
39. Furness JB. The enteric nervous system and neurogastroenterology. Nat Rev Gastroenterol Hepatol 2012; 9: 286–94.
40. Psichas A, Reimann F, Gribble FM. Gut chemosensing mechanisms. J Clin Invest 2015; 125: 908–17.
41. Sjovall H. Meaningful or redundant complexity – mechanisms behind cyclic changes in gastroduodenal pH in the fasting state. Acta Physiol (Oxf) 2011; 201: 127–31.
42. Helander HF, Fandriks L. Surface area of the digestive tract – revisited. Scand J Gastroenterol 2014; 49: 681–9.
43. Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders. Trends Mol Med 2015; 21: 702–14.
44. Vitek L, Haluzik M. The role of bile acids in metabolic regulation. J Endocrinol 2016; 228: R85–96.
45. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147–91.
46. Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001; 280: G922–9.
47. Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol 2013; 10: 352–61.
48. Allen A, Flemstrom G. Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005; 288: C1–19.
49. Johansson M, Synnerstad I, Holm L. Acid transport through channels in the mucous layer of rat stomach. Gastroenterology 2000; 119: 1297–304.
50. Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008; 105: 15064–9.
51. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799–809.
52. Clevers HC, Bevins CL. Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol 2013; 75: 289–311.
53. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nat Rev Mol Cell Biol 2014; 15: 19–33.
54. Schulz O, Pabst O. Antigen sampling in the small intestine. Trends Immunol 2013; 34: 155–61.
55. Karlsson F, Tremaroli V, Nielsen J, Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013; 62: 3341–9.
56. Brestoff JR, Artis D. Commensal bacteria at the interface of host metabolism and the immune system. Nat Immunol 2013; 14: 676–84.
57. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915–20.
58. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PloS Biol 2016; 14: e1002533.
59. Gill SR, Pop M, Deboy RT et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355–9.
60. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242–9.
61. Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol 2014; 28: 1221–38.
62. Utzschneider KM, Kratz M, Damman CJ, Hullarg M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab 2016; 101: 1445–54.
63. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027–31.
64. Li SS, Zhu A, Benes V et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 2016; 352: 586–9.
65. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913–6 e7.
66. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 2012; 13: 275–86.
67. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359–404.
68. le Roux CW, Bueter M, Theis N et al. Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol 2011; 301: R1057–66.
69. Henderson J. Ernest Starling and ‘Hormones’: an historical commentary. J Endocrinol 2005; 184: 5–10.
70. Woods SC. The control of food intake: behavioral versus molecular perspectives. Cell Metab 2009; 9: 489–98.
71. Hamr SC, Wang B, Swartz TD, Duca FA. Does nutrient sensing determine how we “see” food? Curr Diab Rep 2015; 15: 604.
72. Murray CD, Kamm MA, Bloom SR, Emmanuel AV. Ghrelin for the gastroenterologist: history and potential. Gastroenterology 2003; 125: 1492–502.
73. Meek CL, Lewis HB, Reimann F, Gribble FM, Park AJ. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016; 77: 28–37.
74. Muller TD, Nogueiras R, Andermann ML et al. Ghrelin. Mol Metab 2015; 4: 437–60.
75. Wren AM, Bloom SR. Gut hormones and appetite control. Gastroenterology 2007; 132: 2116–30.
76. Farr OM, Sofopoulos M, Tsoukas MA et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia 2016; 59: 954–65.
77. le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 2007; 246: 780–5.
78. Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013; 37: 1553–9.
79. Brighton CA, Rievaj J, Kuhre RE et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology 2015; 156: 3961–70.
80. Trabelsi MS, Daoudi M, Prawitt J et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 2015; 6: 7629.
81. Granger DN, Holm L, Kvietys P. The Gastrointestinal Circulation: physiology and Pathophysiology. Compr Physiol 2015; 5: 1541–83.
82. Jensen MD, Johnson CM, Cryer PE, Murray MJ. Thermogenesis after a mixed meal: role of leg and splanchnic tissues in men and women. Am J Physiol 1995; 268: E433–8.
83. Cant JP, McBide BW, Croom WJ Jr. The regulation of intestinal metabolism and its impact on whole animal energetics. J Anim Sci 1996; 74: 2541–53.
84. Schutz Y, Bessard T, Jequier E. Diet-induced thermogenesis measured over a whole day in obese and nonobese women. Am J Clin Nutr 1984; 40: 542–52.
85. Tappy L. Thermic effect of food and sympathetic nervous system activity in humans. Reprod Nutr Dev 1996; 36: 391–7.
86. Marques-Lopes I, Forga L, Martinez JA. Thermogenesis induced by a high-carbohydrate meal in fasted lean and overweight young men: insulin, body fat, and sympathetic nervous system involvement. Nutrition 2003; 19: 25–9.
87. van Baak MA. Meal-induced activation of the sympathetic nervous system and its cardiovascular and thermogenic effects in man. Physiol Behav 2008; 94: 178–86.
88. Blouet C, Schwartz GJ. Duodenal lipid sensing activates vagal afferents to regulate non-shivering brown fat thermogenesis in rats. PLoS One 2012; 7: e51898.
89. Ravussin E, Galgani JE. The implication of brown adipose tissue for humans. Annu Rev Nutr 2011; 31: 33–47.
90. Werling M, Olbers T, Fandriks L et al. Increased postprandial energy expenditure may explain superior long term weight loss after Roux-en-Y gastric bypass compared to vertical banded gastroplasty. PLoS One 2013; 8: e60280.
91. Werling M, Fandriks L, Olbers T et al. Roux-en-Y gastric bypass surgery increases respiratory quotient and energy expenditure during food intake. PLoS One 2015; 10: e0129784.
92. Spak E, Bjorklund P, Helander HF et al. Changes in the mucosa of the Roux-limb after gastric bypass surgery. Histopathology 2010; 57: 680–8.
93. Saeidi N, Meoli L, Nestoridi E et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 2013; 341: 406–10.
94. Makinen J, Hannukainen JC, Karmi A et al. Obesity-associated intestinal insulin resistance is ameliorated after bariatric surgery. Diabetologia 2015; 58: 1055–62.
95. Magkos F, Bradley D, Eagon JC, Patterson BW, Klein S. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on gastrointestinal metabolism of ingested glucose. Am J Clin Nutr 2016; 103: 61–5.
96. Tremaroli V, Karlsson F, Werling M et al. Roux-en-Y gastric bypass and vertical banded gastroplasty induce long-term changes on the human gut microbiome contributing to fat mass regulation. Cell Metab 2015; 22: 228–38.
97. Chevalier C, Stojanovic O, Colin DJ et al. Gut microbiota orchestrates energy homeostasis during cold. Cell 2015; 163: 1360–74.
98. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. Diabetes Care 2016; 39: 884–92.
99. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60: 470–512.
100. Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 2013; 36: 1396–405.
101. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)–preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009; 23: 463–77.
102. Mithieux G, Gautier-Stein A. Intestinal glucose metabolism revisited. Diabetes Res Clin Pract 2014; 105: 295–301.
103. Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 2012; 18: 950–5.
104. Duca FA, Sakar Y, Covasa M. The modulatory role of high fat feeding on gastrointestinal signals in obesity. J Nutr Biochem 2013; 24: 1663–77.
105. De Vadder F, Kovatcheva-Datchary P, Goncalves D et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014; 156: 84–96.
106. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
107. Straznicky N, Grassi G, Esler M et al. European Society of Hypertension Working Group on Obesity Antihypertensive effects of weight loss: myth or reality? J Hypertens 2010; 28: 637–43.
108. Hallersund P, Sjostrom L, Olbers T et al. Gastric bypass surgery is followed by lowered blood pressure and increased diuresis – long term results from the Swedish Obese Subjects (SOS) study. PLoS One 2012; 7: e49696.
109. Changchien EM, Ahmed S, Betti F et al. B-type natriuretic peptide increases after gastric bypass surgery and correlates with weight loss. Surg Endosc 2011; 25: 2338–43.
110. Abrahamsson N, Engstrom BE, Sundbom M, Karlsson FA. Gastric bypass surgery elevates NT-ProBNP levels. Obes Surg 2013; 23: 1421–6.
111. Bonfils PK, Taskiran M, Damgaard M et al. Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients. J Hypertens 2015; 33: 1215–25.
112. Mu JY, Hansson GC, Lundgren O. The intestinal tract and the pathophysiology of arterial hypertension: an experimental study on Dahl rats. Acta Physiol Scand 1995; 155: 137–46.
113. Stricker EM, Hoffmann ML. Presystemic signals in the control of thirst, salt appetite, and vasopressin secretion. Physiol Behav 2007; 91: 404–12.
114. Bourque CW. Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci 2008; 9: 519–31.
115. Michell AR, Debnam ES, Unwin RJ. Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. Annu Rev Physiol 2008; 70: 379–403.
116. Singer DR, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA. Contrasting endocrine responses to acute oral compared with intravenous sodium loading in normal humans. Am J Physiol 1998; 274: F111–9.
117. Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol 2014; 99: 1140–5.
118. Jose PA. Gastrorenal communication: sniffing and tasting. Exp Physiol 2016; 101: 457–8.
119. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309–16.
120. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118: 993–1001.
121. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting triglycerides and risk of for myocardial infarction and death among women and men. JAMA 2007; 298: 299–308.
122. Idei M, Hirayama S, Miyake N et al. Mean postprandial triglyceride concentration is an independent risk factor for carotid atherosclerosis in patients with type 2 diabetes. Clin Chim Acta 2014; 430: 134–9.
123. Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med 2012; 2012: 947417.
124. Boren J, Matikainen N, Adiels M, Taskinen MR. Postprandial hypertriglyceridemia as a coronary risk factor. Clin Chim Acta 2014; 431: 131–42.
125. Couture P, Tremblay AJ, Kelly I, Lemelin V, Droit A, Lamarche B. Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance. J Lipid Res 2014; 55: 128–37.
126. Abumrad NA, Davidson NO. Role of the gut in lipid homeostasis. Physiol Rev 2012; 92: 1061–85.
127. Dash S, Xiao C, Morgantini C, Lewis GF. New insights into the regulation of chylomicron production. Annu Rev Nutr 2015; 35: 265–94.
128. Demignot S, Beilstein F, Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in enterocytes: key players in intestinal physiology and metabolic disorders. Biochimie 2014; 96: 48–55.
129. Robertson MD, Parkes M, Warren BF et al. Mobilisation of enterocyte fat stores by oral glucose in humans. Gut 2003; 52: 834–9.
130. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest 2003; 33: 976–82.
131. Lee SD, Gershkovich P, Darlington JW, Wasan KM. Inhibition of cholesterol absorption: targeting the intestine. Pharm Res 2012; 29: 3235–50.
132. https://health.gov/dietaryguidelines/2015/ (accessed June 12 2016). 2015.
133. Amiot MJ, Knol D, Cardinault N et al. Phytosterol ester processing in the small intestine: impact on cholesterol availability for absorption and chylomicron cholesterol incorporation in healthy humans. J Lipid Res 2011; 52: 1256–64.
134. Gylling H, Simonen P. Phytosterols, phytostanols, and lipoprotein metabolism. Nutrients 2015; 7: 7965–77.
135. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15–22.
136. Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003; 25: 2352–87.
137. Lin X, Racette SB, Lefevre M et al. Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation 2011; 124: 596–601.
138. Smits MM, van Raalte DH, Tonneijck L, Muskiet MH, Kramer MH, Cahen DL. GLP-1 based therapies: clinical implications for gastroenterologists. Gut 2016; 65: 702–11.
139. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia 2016; 59: 426–35.
140. Ait-Omar A, Monteiro-Sepulveda M, Poitou C et al. GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes 2011; 60: 2598–607.
141. Monteiro-Sepulveda M, Touch S, Mendes-Sa C et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab 2015; 22: 113–24.
142. Hodge RJ, Paulik MA, Walker A et al. Weight and glucose reduction observed with a combination of nutritional agents in rodent models does not translate to humans in a randomized clinical trial with healthy volunteers and subjects with type 2 diabetes. PLoS One 2016; 11: e0153151.